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Abstract 
Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia and is characterized 
by hypercalcemia and levels of parathyroid hormone (PTH) that are inappropriately high for the 
hypercalcemic state. The clinical presentation of PHPT has evolved over the past 40 years to include 
three distinct clinical phenotypes: the classical symptomatic disorder, the asymptomatic disorder and the 
normocalcemic disorder (1). 
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Introduction  
In PHPT serum calcium levels are elevated in the context of non suppressed parathyroid 
hormone levels. Approximately 80% of patients with PHPT have a single parathyroid 
adenoma, 10% have more than one adenoma, and less than 10% have hyperplasia of all four 
gland. Parathyroid carcinoma causes less than 1% of cases of hyperparathyroidism (1). 
Patients with mild hyperparathyroidism are at increased risk for renal stones, cortical bone 
loss, and fractures. Evaluation should include measures of serum calcium, intact parathyroid 
hormone, 25-hydroxyvitamin D, glomerular filtration rate, 24-hour urine calcium excretion, 
and bone density (including the distal third of the radius), as well as a renal ultrasound 
examination to detect stones (2). 
Clinical Case 1 
A 56-year-old woman had a fasting serum calcium level of 11.4 mg /dl (reference range 8.4 
to 10.2), the serum phosphorus level is 2.0 mg/dl and the parathyroid hormone (PTH) level is 
98 pg/ml (reference range 11 to 67). She presented normal renal function and BMD with 
vertebral T-score of –1.6. A diagnosis of Asymptomatic Primary Hyperparathyroidism was 
made. To localize abnormal parathyroid tissue, neck ultrasound was negative and 
technetium-99m sestamibi scanning shows a left paratracheal ectopic parathyroid adenoma 
confirmed by CT imaging. (Fig 1). 
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After six months the serum Ca was 11.2, P 2.0 and PTH 102, and Cinacalcet therapy,  at dose 
of 15 mg/day, was started. After two years the serum Ca was 10.1 and PTH 65 pg/dl,  but 
vertebral BMD worsened (T-score – 2.5) and Alendronate  70 mg/weekly was added to 
Cinacalcet. 
Fig 1. Case 1: Ectopic left paratracheal parathyroid 
  
Clinical Case 2  
In a 68-year-old man with serum calcium level of 14.1 mg/dl and PTH level of 132 pg/ml 
was made a diagnosis of Primary Hyperparathyroidism by Adenoma of parathyroid lower 
right confirmed at ultrasound, sestamibi-scanning and CT imaging; Fig 2.  He was operated 
and two months after surgery his serum Ca was 10 mg/dl and PTH level 65 pg/ml.  After 
eight months serum calcium was 12.5 mg/dl and PTH level 57 pg/ml with hypercalciuria 
(>400 mg/day) and a Persistent or Recurrent Primary Hyperparathyroidism was diagnosed, 
without any hyperplasia parathyroid imaging.  
Fig 2. Case 2; a: ultrasound and b: sestamibi lower right parathyroid  
 
 
Discussion  
Surgery remains the only definitive treatment for hyperparathyroidism. Guidelines from the 
4th International Workshop (3) recommend surgery for patients younger than 50 years of age 
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and for patients with clinically significant hypercalcemia (>1 mg/dl above normal), 
osteoporosis (T-score -2.5) or a fragility fracture, renal calculi, hypercalciuria (especially 
with a lithogenic urine biochemical profile), or impaired renal function (creatin ine clearance 
<60 ml/min); Tab. 1. 
In a 15-year retrospective study, patients who received a surgical cure had a 10-year absolute 
risk of hip fracture that was 64% lower than that among patients who had not received any 
treatment (4). Randomized, controlled trials have not consistently 
shown alleviation of  PHPT- related neurocognitive and emotional symptoms after surgical 
cure (5). Similarly, whether surgery reduces the cardiovascular disease risk associated with 
hyperparathyroidism remains unclear. 
Like clinical case 1, for patients who decline or are not candidates for surgery, medical 
therapies have been used to address hypercalcemia, bone disease and hypercalciuria in 
hyperparathyroidism; Tab. 2. Deficiencies in vitamin D and dietary calcium worsen 
hyperparathyroidism, so patients should have a calcium-sufficient diet and maintain a serum 
25-hydroxyvitamin D level in the range of 20 to 30 ng/ml (6). Cinacalcet is an activator of 
the of the calcium sensing receptor and in hyperparathyroidism sensitizes that receptor to 
serum calcium which, when activated, suppresses the secretion of  PTH. In a descriptive, 
prospective, observational study in hospital and specialist care centers, reductions in calcium 
levels of >1 mg/dl was observed in 60% of patients 12 months after initiation of cinacalcet, 
without notable safety concerns (7), but cinacalcet had no significant effect on bone loss like 
in clinical case 1. The bisphosphonate, alendronate, improves the lumbar spine BMD without 
any changes in the serum calcium (8). Very recently, denosumab has been evaluated in 
women with PHPT and after 2 years showed increases in BMD at lumbar spine, total hip and 
femoral neck (9)  
 
Table 1. Indications for surgery in asymptomatic primary hyperparathyroidism 
age <50 years 
Serum calcium >1 mg/dl above upper limit of normal 
Skeletal 
manifestations 
Reduced BMD to a score of -2.5 at any site 
Renal manifestations Creatinine clearance <60 ml/min 
Kidney stone or nephrocalcinosis 
Hypercalciuria >400 mg/day 
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Table 2. Response to medication in patients with PHPT 
 
 
In the clinical case 2, the serum calcium returned high after 10 months of surgery with PTH 
level non suppressed and without any enlarged parathyroid imaging. 
Persistent primary hyperparathyroidism is when the calcium and PTH levels do not return to 
normal levels after the operation or became abnormal again within 6 months of the operation. 
Persistent primary hyperparathyroidism usually happens because not all of the abnormal 
parathyroid tissue was removed at the first operation. This can happen if an inexperienced 
surgeon "misses" the diseased gland or if there is an ectopic gland located in a difficult to 
find location or if the patient has multiple abnormal glands. Recurrent primary 
hyperparathyroidism is when the calcium and PTH levels initially are normal but after 6 
months again become abnormal. Recurrent hyperparathyroidism usually happens when one 
or more of the remaining glands becomes hyperactive. This is a new problem and does not 
reflect a "missed gland" at the first operation (10). Although parathyroid imaging is not 
necessary to establish a diagnosis of primary hyperparathyroidism, four preoperative imaging 
methods are routinely used to localize abnormal parathyroid (11-13); Fig 3 and Table 3. 
Surgical treatment of hyperparathyroidism should incorporate intraoperative PTH 
measurements where available. After removal of a single adenoma, the intraoperative PTH 
should decrease by at least 50% and into the normal range. Intraoperative measurements of 
PTH are particularly valuable when more than one gland is abnormal (14).  
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Fig. 3. Parathyroid Imaging. Panel A shows a longitudinal ultrasonographic image of the right 
parathyroid. Panel B shows a delayed-phase planar sestamibi scan indicating a marked uptake 
at the level of the right thyroid lobe. In Panel C, a delayed-phase sestamibi scan shows a 
marked uptake at the level of the middle mediastinum (arrow). In Panel D, a magnetic 
resonance imaging scan of the chest shows a lesion in the aortopulmonary window (arrow)  
 
Table 3. Preoperative imaging method used to localize abnormal parathyroid 
 
Imaging Method sensitivity PPV  
Ultrasonography 70.4-81.4% 90.7-95.3 % Safe, no radiations 
Technetium-99msestamibi scanning 64-90.6% 83.5-96 % Can be used to detect ectopic 
parathyrid tissue 
Dynamic (4D) CT imaging 89.4% 93.5% Useful for identifying multiple 
adenomas 
Magnetic resonance imaging 88% 90% Same principles as CT imaging, but 
obviates concerns about radiation 
Summary 
Surgery in PHPT offers the promise of definitive cure. Surgery does not correct cardiovascular 
abnormalities in hyperparathyroidism, and whether it alleviates psychiatric and cognitive deficits is 
a subject of controversy. 
Medical management includes correction of dietary calcium and vitamin D insufficiency. 
Cinacalcet lowers serum calcium levels but does not affect rates of bone loss. Bisphosphonates 
improve bone density, but whether they reduce the risk of fracture is unknow 
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